<DOC>
	<DOCNO>NCT02356991</DOCNO>
	<brief_summary>Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 . Phase I study show toxicity manageable . The purpose study evaluate efficacy safety profile Famitinib patient Advanced Non-squamous Non-Small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Famitinib Patients With Advanced Non-squamous Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1.Age : 1870 ; 2.Advanced ( IV phase ) non squamous NSCLC confirm pathology , measurable lesion ( tumour lesion ≥10mm long diameter , malignant lymph node ≥15mm short axis , scan layer ≤ 5 mm , measurable lesion receive locoregional theraphy , radiotherapy frozen therapy ) ; 3.Previously treat EGFR inhibitor chemotherapy , second line treatment failure : a.for EGFR wild type , second line treatment failure ( least previously treat platinumbased chemotherapy ) b.for EGFR mutation type , third line treatment failure ( least previously treat Platinumbased chemotherapy EGFR inhibitor ) 4.ECOG Performance Status 0 1 ; 5.Life expectancy least 3 month ; 6.Damage cause antitumor therapy restore , nitroso mitomycin treatment interval ≥ 6 week ; cytotoxic drug , radiotherapy surgery ≥ 4 week ; EGFR molecular target drug ≥ 2 week ; 7.Participants inadequate organ marrow function define : Hemoglobin ≥ 90g/L ( blood transfusion 2 week ) Absolute neutrophil count ( ANC ) ≥ 1.5×10^9/L PLT ≥ 80×10^9/L Bilirubin ＜ 1.25 × ULN ALT ＜ 2.5 × ULN AST ＜ 2.5 × ULN serum creatinine ＜ 1.25 × ULN , endogenous Cr clearance ＞ 45 ml/min ( CockcroftGault Formula ) cholesterol ≤ 1.5×ULN triglyceride≤ 2.5 × ULN LVEF≥ LLN Color Doppler Ultrasonography 8.Female : Child bear potential , negative urine serum pregnancy test result 7 day initiate famitinib.All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 8 week last dose test article . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 8 week last dose test article ; 9.Ability understand willingness sign write informed consent . Good compliance followup visit . 1.Squamous cell carcinoma ( include adenosquamous carcinoma , undifferentiated carcinoma ) ; small cell lung cancer ( lung cancer include small cell carcinoma nonsmall cell hybrid ) ; 2.Known brain metastasis , spinal cord compression , cancer meningitis , screen CT MRI examination reveal brain leptomeningeal disease 3.Patients hypertension use combination therapy ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) . Patients Class I , myocardial ischemia myocardial infarction , arrhythmia ( include QT interval ≥ 450ms male 470ms female ) class II cardiac dysfunction , accord NCICTC AE 4.0 ; 4.Variety factor affect oral medication ( inability swallow , gastrointestinal resection , chronic diarrhea intestinal obstruction ) ; 5.Coagulation abnormality ( PT PTINR &gt; 1.5 ULN , APTT &gt; 1.5 ULN ) , bleed tendency ( eg , active peptic ulcer ) receive thrombolytic anticoagulant therapy ; 6.Distance tumour lesion major blood vessel radiographical evidence ( CT MRI ) ≥5mm . 7.Pulmonary hemorrhage/ bleed event ≥ CTCAE gr . 1 （including Hemoptysis≥2.5ml half teaspoon）within four week first dose study drug ; Any hemorrhage/ bleeding event ≥ CTCAE gr . 2 within four week first dose study drug ; 8.Longterm untreated wound fracture ; 9.Thrombotic embolic venous arterial event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 12 month prior first dose study drug ; 10.Urine protein ≥ + + confirm 24hour urinary protein &gt; 1.0 g ; 11.Application anticoagulant vitamin K antagonist warfarin , heparin analogue ; If prothrombin time international normalize ratio ( INR ) ≤ 1.5 , purpose prevention , use small dos warfarin ( 1mg orally , daily ) ，lowdose heparin ( 0.6~1.2 ×10^8 U daily ) lowdose aspirin ( less 100mg daily ) allow ; 12.Preexisting thyroid dysfunction , even use medical therapy , thyroid function maintain normal range ; 13.Preexisting ascites and/or clinically significant pleural effusion ; 14.Active hepatitis C and/or B infection ; 15.Abuse psychiatric drug dysphrenia ; 16.Participated anticancer clinical trial within four week ; 17.Prior therapy VEGFR inhibitor，except Bevacizumab ( Avastin ) ; 18.Past suffering cancer , cure basal cell carcinoma cervical carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Famitinib</keyword>
	<keyword>Phase II</keyword>
	<keyword>NSCLC</keyword>
</DOC>